Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Drug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Fineline Cube Mar 14, 2025

China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...

Company Drug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Fineline Cube Mar 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Company Deals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Fineline Cube Mar 14, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...

Company Medical Device

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st

Fineline Cube Mar 14, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...

Company Drug

China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM

Fineline Cube Mar 14, 2025

China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...

Company Drug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

Fineline Cube Mar 14, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...

Company Drug

Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials

Fineline Cube Mar 14, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...

Company Medical Device

Johnson & Johnson MedTech Gains FDA Clearance for MONARCH QUEST with AI Algorithms

Fineline Cube Mar 14, 2025

US major Johnson & Johnson MedTech announced receiving U.S. 510(k) regulatory clearance for its MONARCH...

Company Drug

Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer

Fineline Cube Mar 14, 2025

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...

Company

Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges

Fineline Cube Mar 14, 2025

China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...

Company Deals

Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology

Fineline Cube Mar 14, 2025

France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...

Company Deals

Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies

Fineline Cube Mar 14, 2025

China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...

Company Deals

Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management

Fineline Cube Mar 14, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...

Policy / Regulatory

China Issues Guidelines for Informatization of Compact County-level Medical Communities

Fineline Cube Mar 14, 2025

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Drug Policy / Regulatory

CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 14, 2025

China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...

Medical Device Policy / Regulatory

China’s NHSA Issues Guidelines for Neurological Medical Services Pricing

Fineline Cube Mar 14, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...

Company

Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth

Fineline Cube Mar 14, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...

Posts pagination

1 … 210 211 212 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.